Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seralutinib - Gilead Sciences/Gossamer Bio

Next Previous
Drug Profile

Seralutinib - Gilead Sciences/Gossamer Bio

Alternative Names: GB-002; PK-10571

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator YM BioSciences
  • Developer Gossamer Bio
  • Class Amides; Antihypertensives; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary arterial hypertension

Most Recent Events

  • 05 Mar 2024 PMDA of Japan approves clinical trial application for phase-III PROSERA trial in Pulmonary arterial hypertension (Inhalation) prior to March 2024
  • 27 Feb 2024 Gossamer Bio plans the phase III PROSERA-EXT trial for Pulmonary arterial hypertension in USA in June 2024 (Inhalation, capsule) (NCT06274801) (EudraCT 2023-5063-3475)
  • 31 Dec 2023 Gossamer Bio has patents pending for combination treatment with seralutinib
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top